Vertex Pharmaceuticals

Biotechnology

VRTX

$ 350 (1.1)%

Share price

$ 90 bn

Market Cap

$ 79 bn

Enterprise Value

Carbon footprint

GHG emissions per $ 1 mln investment

0x the weighted average for S&P 500

FY2021

Primary Climate Goal

Proj. YOY change in GHG emissions (Scope 1 + 2)

Weaker than the -8.2% weighted average for S&P 500

FY2022

Vertex Pharmaceuticals aims to reduce Scope 1 + 2 by 20% by 2023 from a base year 2018

This target is most likely outdated and the company appears to have already achieved it

This target has not been verified as science based according to SBTi

GHG emissions and Carbon intensity

Vertex Pharmaceuticals reported Total CO2e Emissions - Market-Based Scope 1 + Scope 2 for the twelve months ending 31 December 2021 at 13 Kt (-0.16 /-1.2% y-o-y). Also positively, carbon intensity decreased to 1.8 t (-0.4 /-18.2% y-o-y).

No public disclosure of Scope 3 emissions has been found for Vertex Pharmaceuticals at the moment.

The company is committed to reducing Scope 1 + 2 by 20% by 2023 from a base year 2018, which it appears to have already achieved as of 2021. This target, however, has not been recognised as science-based (and as aligned with Paris Agreement) by the SBTi.

Date	Total CO2e emissions (market-based Scope 1 & 2) (Kt)	Scope 1	Scope 2	Revenue (USDm)	Carbon intensity (tons of CO2e) / (USDm)
2021Q4	13	6.1	7.2	7,574	1.8
2020Q4	13	5.6	7.8	6,206	2.2
2019Q4	14	5.8	8	4,163	3.3
2018Q4	17	5.7	11	3,048	5.4
2017Q4	17	6	11	2,489	6.9